Blood type tied to prognosis in hepatocellular carcinoma
Blood type is associated with prognosis in Chinese hepatocellular carcinoma (HCC) patients, a new study reveals. Those with non-O blood types particularly have poorer overall survival (OS).
Over a median follow-up of 36 (25 to 75) months, 392 of the 691 HCC patients who received hepatectomy died. The 3- and 5-year survival rates were 52.9 and 38.7 percent, respectively.
Blood group was significantly associated with OS (p=0.001). The median OS for blood type O was 55 (95 percent CI, 42.69 to 67.31) months, type A 39 (32.20 to 45.80) months, type B 34 (26.58 to 41.42) months and type AB 34 (24.09 to 43.91) months.
Because the 1-, 3- and 5-year OS values for the blood type O group (88.2, 58.8 and 47.3 percent, respectively) were significantly higher than the type A/B/AB groups, which had comparable OS values (p=0.226), the study cohort was divided into O vs non-O blood type groups.
The resulting median OS for the blood type O group was 55 (42.69 to 67.30) months vs 36 (31.18 to 40.81) months for the non-O blood type group. Patients with blood type O had significantly better survival than those with non-O blood types (1-year OS, 88.2 vs 83.4 percent; 3-year OS, 58.5 vs 49.1 percent; 5-year OS, 47.3 vs 30.5 percent; p<0.001 for all).
Multivariate Cox regression analysis revealed that blood types A (hazard ratio [HR], 1.416; 95 percent CI, 1.101 to 1.820; p=0.007), B (HR, 1.736; 1.333 to 2.262; p<0.001) and AB (HR, 1.739; 1.210 to 2.499; p=0.006) were significant poor prognostic factors for HCC following hepatectomy.
The non-O blood type group (HR, 1.485; 1.204 to 1.830; p<0.001) had significantly worse OS compared with the O blood type group.